The results were not satisfying, probably due to the small sample size, high-risk baseline clinical features of participants, and the relatively mild HDAC inhibition capability of AR-42.624 A phase I study investigated decitabine combined with the HDAC inhibitor valproic acid or not in 25 AML patients. This evidence concerns the gene HDAC9 and acute myeloid leukemia.